← Leaderboards
M. Rita Young
Loyola University Chicago
$5,685,619
Attributed
$5,685,619
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $676.4K · FY2005–18$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$5,685,619 · 6
VA$0 · 3
By mechanism
R01$5,685,619 · 6
I01$0 · 3
Top collaborators
No co-investigators on record.
Most similar at Loyola University Chicago
Same institution · by research overlap
- Elizabeth J Kovacs$23,448,857
- Jordan Beach$3,115,548
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsCellsPreventIncidenceMalignant Mouth NeoplasmIn VitroCommon NeoplasmImmuneBaseOral LesionAntigensPublic Health RelevanceDendritic CellsCarcinogensT-LymphocyteLesionPremalignantTumorMouse ModelMouth Squamous Cell CarcinomaExposure ToHigh RiskMediatingAngiogenesis
Grant awards (35)
Dysregulated Immune State in PTSD Contributes to Microglial Inflammation$0
I01 · FY2018 · VA · contact PI
Dysregulated Immune State in PTSD Contributes to Microglial Inflammation$0
I01 · FY2017 · VA · contact PI
Sustaining a Th17 Phenotype to Prevent Premalignant Lesion Progression to Cancer$0
I01 · FY2016 · VA · contact PI
Sustaining a Th17 Phenotype to Prevent Premalignant Lesion Progression to Cancer$0
I01 · FY2015 · VA · contact PI
Sustaining a Th17 Phenotype to Prevent Premalignant Lesion Progression to Cancer$0
I01 · FY2014 · VA · contact PI
Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity$0
I01 · FY2014 · VA · contact PI
Immunotherapy to prevent oral permalignant lesion recurrence and oral cancer.$238,391
R01 · FY2013 · CA · contact PI
Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity$0
I01 · FY2013 · VA · contact PI
Sustaining a Th17 Phenotype to Prevent Premalignant Lesion Progression to Cancer$0
I01 · FY2013 · VA · contact PI
Immunotherapy to prevent oral permalignant lesion recurrence and oral cancer.$253,607
R01 · FY2012 · CA · contact PI
Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity$0
I01 · FY2012 · VA · contact PI
Macrophage-driven progression of premalignant oral lesions toward invasiveness$302,495
R01 · FY2011 · DE · contact PI
Immunotherapy to prevent oral permalignant lesion recurrence and oral cancer.$253,607
R01 · FY2011 · CA · contact PI
Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity$0
I01 · FY2011 · VA · contact PI
Immunotherapy to prevent oral permalignant lesion recurrence and oral cancer.$361,449
R01 · FY2010 · CA · contact PI
Macrophage-driven progression of premalignant oral lesions toward invasiveness$311,850
R01 · FY2010 · DE · contact PI
Macrophage-driven progression of premalignant oral lesions toward invasiveness$315,000
R01 · FY2009 · DE · contact PI
Immunotherapy to prevent oral permalignant lesion recurrence and oral cancer.$261,450
R01 · FY2009 · CA · contact PI
Immunotherapy to prevent oral permalignant lesion recurrence and oral cancer.$99,999
R01 · FY2009 · CA · contact PI
Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity$0
I01 · FY2009 · VA · contact PI
Macrophage-driven progression of premalignant oral lesions toward invasiveness$315,000
R01 · FY2008 · DE · contact PI
Blocking angiogenesis by targeting PP-2A pathways$239,240
R01 · FY2007 · CA · contact PI
Blocking angiogenesis by targeting PP-2A pathways$246,385
R01 · FY2006 · CA · contact PI
Blocking angiogenesis by targeting PP-2A pathways$252,315
R01 · FY2005 · CA
Blocking angiogenesis by targeting PP-2A pathways$252,315
R01 · FY2004 · CA
CONTRIBUTION OF VASCULOGENESIS TO TUMOR VASCULARIZATION$198,450
R01 · FY2004 · CA
Blocking angiogenesis by targeting PP-2A pathways$275,028
R01 · FY2003 · CA
CONTRIBUTION OF VASCULOGENESIS TO TUMOR VASCULARIZATION$198,450
R01 · FY2003 · CA
CONTRIBUTION OF VASCULOGENESIS TO TUMOR VASCULARIZATION$198,450
R01 · FY2002 · CA
CONTRIBUTION OF VASCULOGENESIS TO TUMOR VASCULARIZATION$198,450
R01 · FY2001 · CA
PROTEIN PHOSPHATASES-1 AND-2A RESTRICT TUMOR METASTASIS$197,302
R01 · FY2001 · CA
PHOSPHATASE REGULATION OF TUMOR INDUCED ANGIOGENESIS$155,016
R01 · FY2001 · CA
CONTRIBUTION OF VASCULOGENESIS TO TUMOR VASCULARIZATION$219,312
R01 · FY2000 · CA
PROTEIN PHOSPHATASES-1 AND-2A RESTRICT TUMOR METASTASIS$191,555
R01 · FY2000 · CA
PHOSPHATASE REGULATION OF TUMOR INDUCED ANGIOGENESIS$150,503
R01 · FY2000 · CA